These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30465235)

  • 1. Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls.
    Marques TM; van Rumund A; Bruinsma IB; Wessels HJCT; Gloerich J; Esselink RAJ; Bloem BR; Kuiperij HB; Verbeek MM
    Mol Neurobiol; 2019 Jul; 56(7):5067-5074. PubMed ID: 30465235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics.
    Magdalinou NK; Noyce AJ; Pinto R; Lindstrom E; Holmén-Larsson J; Holtta M; Blennow K; Morris HR; Skillbäck T; Warner TT; Lees AJ; Pike I; Ward M; Zetterberg H; Gobom J
    Parkinsonism Relat Disord; 2017 Apr; 37():65-71. PubMed ID: 28214264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism.
    Constantinescu R; Rosengren L; Eriksson B; Blennow K; Axelsson M
    Acta Neurol Scand; 2019 Aug; 140(2):147-156. PubMed ID: 31070772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms.
    Santaella A; Kuiperij HB; van Rumund A; Esselink RAJ; van Gool AJ; Bloem BR; Verbeek MM
    BMC Neurol; 2020 Jan; 20(1):26. PubMed ID: 31952511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders.
    Herbert MK; Aerts MB; Beenes M; Norgren N; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
    Front Neurol; 2015; 6():91. PubMed ID: 25999911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation.
    Gaetani L; Höglund K; Parnetti L; Pujol-Calderon F; Becker B; Eusebi P; Sarchielli P; Calabresi P; Di Filippo M; Zetterberg H; Blennow K
    Alzheimers Res Ther; 2018 Jan; 10(1):8. PubMed ID: 29370869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease.
    von Euler Chelpin M; Söderberg L; Fälting J; Möller C; Giorgetti M; Constantinescu R; Blennow K; Zetterberg H; Höglund K
    J Parkinsons Dis; 2020; 10(4):1429-1442. PubMed ID: 33016895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes.
    Jabbari E; Woodside J; Guo T; Magdalinou NK; Chelban V; Athauda D; Lees AJ; Foltynie T; Houlden H; Church A; Hu MT; Rowe JB; Zetterberg H; Morris HR
    J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):768-773. PubMed ID: 30867224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T; Sawada J; Kikuchi-Takeguchi S; Kano K; Takahashi K; Saito T; Okizaki A; Hasebe N
    Neurosci Lett; 2020 Jan; 715():134564. PubMed ID: 31733322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
    Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.
    Boman A; Svensson S; Boxer A; Rojas JC; Seeley WW; Karydas A; Miller B; Kågedal K; Svenningsson P
    J Parkinsons Dis; 2016 Apr; 6(2):307-15. PubMed ID: 27061067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
    Constantinescu R; Rosengren L; Johnels B; Zetterberg H; Holmberg B
    Parkinsonism Relat Disord; 2010 Feb; 16(2):142-5. PubMed ID: 19647470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation.
    Shi M; Movius J; Dator R; Aro P; Zhao Y; Pan C; Lin X; Bammler TK; Stewart T; Zabetian CP; Peskind ER; Hu SC; Quinn JF; Galasko DR; Zhang J
    Mol Cell Proteomics; 2015 Mar; 14(3):544-55. PubMed ID: 25556233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic profiling of cerebrospinal fluid in parkinsonian disorders.
    Constantinescu R; Andreasson U; Li S; Podust VN; Mattsson N; Anckarsäter R; Anckarsäter H; Rosengren L; Holmberg B; Blennow K; Wikkelsö C; Rüetschi U; Zetterberg H
    Parkinsonism Relat Disord; 2010 Sep; 16(8):545-9. PubMed ID: 20620095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum NFL discriminates Parkinson disease from atypical parkinsonisms.
    Marques TM; van Rumund A; Oeckl P; Kuiperij HB; Esselink RAJ; Bloem BR; Otto M; Verbeek MM
    Neurology; 2019 Mar; 92(13):e1479-e1486. PubMed ID: 30814322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.